Albert W. Gianchetti
Chief Executive Officer at Xylocor Therapeutics, Inc.
Profile
Albert W.
Gianchetti is currently the President, Chief Executive Officer & Director at Xylocor Therapeutics, Inc. He previously worked as the Chief Commercial Officer & Senior Vice President at Vanda Pharmaceuticals, Inc. from 2007 to 2008 and as the Vice President-Global Commercial Strategy at GSK Plc.
He holds an MBA degree from Drexel University and an undergraduate degree from the University of Delaware.
Albert W. Gianchetti active positions
| Companies | Position | Start |
|---|---|---|
Xylocor Therapeutics, Inc.
 Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | Chief Executive Officer | - |
Former positions of Albert W. Gianchetti
| Companies | Position | End |
|---|---|---|
| VANDA PHARMACEUTICALS INC. | Corporate Officer/Principal | 2008-11-30 |
| GSK PLC | Corporate Officer/Principal | - |
Training of Albert W. Gianchetti
| Drexel University | Masters Business Admin |
| University of Delaware | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| VANDA PHARMACEUTICALS INC. | Health Technology |
| GSK PLC | Health Technology |
| Private companies | 1 |
|---|---|
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | Health Technology |
- Stock Market
- Insiders
- Albert W. Gianchetti
